source
- Teva's experimental antibody cuts intestinal damage in celiac patients after gluten challengeTeva reported that a single injection of an experimental antibody markedly lowered intestinal damage in participants with celiac disease who continued to consume gluten daily. The study was a glut…
- Teva reports positive mid-stage results for celiac disease antibody, BioMarin settles patent fight with AscendisTeva said its experimental antibody TEV-408 showed statistically significant and clinically meaningful reduction in gluten-induced intestinal damage in a mid-stage trial for celiac disease. The tr…